Takeda holder plans $0.86M ADS sale under Rule 144

Takeda Pharmaceutical Company Limited has a holder planning a resale of its American Depositary Shares under Rule 144.

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited has a holder planning a resale of its American Depositary Shares under Rule 144. The plan covers 51,579 ADSs to be sold through Interactive Brokers LLC on the NYSE, with an aggregate market value of $863,947.36. The securities relate to Restricted Stock Unit Awards – Vested, with 109,202 ADSs acquired as compensation on July 1, 2026, of which a portion is covered by this planned sale as of a proposed sale date of July 13, 2026.

Filing Explained

This is a proposed, compensation-related ADS sale notice, with no completed sale or issuer dilution disclosed.

The July 13, 2026 Form 144 reports securities to be sold, so it records a proposed ADS sale rather than a completed sale; it discloses no issuer-level issuance, proceeds, or dilution for Takeda Pharmaceutical Company Limited or its existing common holders.

The filing lists 51579 ADSs for sale; the filing does not show proceeds received.

The ADSs are identified as acquired on July 1, 2026 through vested restricted stock unit awards, with compensation listed as the payment basis; no sale price is shown in the supplied filing.

The filing does not provide the filer's remaining ADS holdings, so the change in that filer's position cannot be sized from this record.

A later filing or trade record would be needed to establish whether the proposed sale was completed; this Form 144 alone does not do so.

Key Figures

ADSs to be sold: 51,579 ADSs Aggregate market value: $863,947.36 ADSs acquired via RSU vesting: 109,202 ADSs +1 more

4 metrics

ADSs to be sold 51,579 ADSs Planned Rule 144 sale through Interactive Brokers LLC on the NYSE

Aggregate market value $863,947.36 Value of 51,579 ADSs covered by the planned Rule 144 sale

ADSs acquired via RSU vesting 109,202 ADSs Restricted Stock Unit Awards – Vested as compensation on July 1, 2026

Proposed sale date July 13, 2026 Date associated with the planned sale of ADSs on the NYSE

Key Terms

American Depositary Shares (ADSs), Restricted Stock Unit Awards - Vested, compensation

3 terms

American Depositary Shares (ADSs) financial

"American Depositary Shares (ADSs) | Interactive Brokers LLC"

A U.S.-listed certificate that stands for a specific number of shares in a non‑U.S. company held by a U.S. bank, making the foreign stock tradable on American exchanges in dollars. Think of it like a local voucher that represents ownership of an overseas product — it lets U.S. investors buy and sell foreign companies without handling foreign currency or foreign brokerage accounts, but it can affect dividends, voting rights, fees, liquidity and exposure to currency and regulatory differences.

Restricted Stock Unit Awards - Vested financial

"ADSs | 07/01/2026 | Restricted Stock Unit Awards - Vested."

compensation financial

"109202 | 07/01/2026 | Compensation"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What volume of Takeda (TAK) ADSs is covered by this Rule 144 sale notice?

The notice covers up to 51,579 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited. These shares have an aggregate market value of $863,947.36 and are proposed to be sold on the NYSE through Interactive Brokers LLC.

How were the Takeda (TAK) ADSs in this Form 144 acquired?

The ADSs are tied to Restricted Stock Unit Awards – Vested. A total of 109,202 ADSs were acquired as compensation on July 1, 2026, and a portion of these is included in the planned Rule 144 sale.

What is the proposed sale date for the Takeda (TAK) ADSs in this filing?

The filing lists a proposed sale date of July 13, 2026 for the 51,579 ADSs covered by the notice. The transactions are expected to occur on the NYSE through Interactive Brokers LLC, subject to Rule 144 conditions.

What is the aggregate market value of Takeda (TAK) ADSs to be sold?

The planned sale under Rule 144 covers ADSs with an aggregate market value of $863,947.36. This valuation corresponds to the 51,579 ADSs listed for possible sale on the NYSE via Interactive Brokers LLC.

Which broker is handling the planned Takeda (TAK) ADS Rule 144 sale?

The planned sale of 51,579 ADSs is to be executed through Interactive Brokers LLC, located at One Pickwick Plaza, Greenwich, CT 06830. The ADSs are listed for trading on the NYSE under this Rule 144 notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 06:26 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001977746
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Takeda Pharmaceutical Company Limited
SEC File Number
Address of Issuer	1-1, Nihonbashi-Honcho 2-chome, Chuo-ku Tokyo JAPAN 103-8668
Phone	81-3-3278-2306
Name of Person for Whose Account the Securities are To Be Sold	Lauren Rusckowski Duprey
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Chief Transformation Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	51579	863947.36	143310556	07/13/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2026	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			109202	07/01/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	07/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kate Huleatt, by power of attorney, for Lauren Rusckowski Duprey
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)